Heparin-induced thrombocytopenia Type II (HIT II) is a serious complication that occurs in 0.2–3% of patients treated with heparin and is associated with a high risk of thrombotic events. One center recently reported an incidence of HIT II of 15% in a population of patients with aneurysmal subarachnoid hemorrhage (aSAH). Because these patients are typically exposed to heparin during angiography, controversy exists regarding whether prophylaxis with enoxaparin rather than heparin affords any reduction in the risk of developing HIT II. In this study, the authors investigated the effect of heparin compared with enoxaparin on the incidence of HIT II in patients with aSAH.
The authors reviewed the medical records of 300 patients treated for aSAH who received thromboprophylaxis with either heparin or enoxaparin, and identified patients who developed HIT II. The incidences of HIT II in the 2 treatment groups were then compared.
One hundred sixty-six patients with aSAH were treated with heparin, and 134 patients were treated with enoxaparin. Sixteen (5.3%) of 300 patients met the diagnostic criteria for HIT II. Of those treated with heparin, 8 (4.8%) of 166 developed HIT II, compared with 8 (6%) of 134 treated with enoxaparin (difference not significant).
The authors report a lower incidence of HIT II in patients with aSAH than has previously been reported. The data also suggest that patients with aSAH who receive heparin are at no greater risk of developing HIT II than those who receive enoxaparin. This finding challenges the merit of choosing enoxaparin rather than heparin for thromboprophylaxis in patients with a SAH.
Abbreviations used in this paper: aSAH = aneurysmal subarachnoid hemorrhage; DVT = deep venous thrombosis; HIT II = heparininduced thrombocytopenia Type II; ICU = intensive care unit; LMWH = low-molecular-weight heparin; SD = standard deviation.
Address correspondence to: Grace H. Kim, M.D., Department of Neurological Surgery, Columbia College of Physicians and Surgeons, Neurological Institute of New York, 630 West 168th Street, Room 5-462, New York, New York 10032. email:
Please include this information when citing this paper: published online October 31, 2008; DOI: 10.3171/2008.3.17480.
AgnelliGPiovellaFBuoncristianiPSeveriPPiniMD'AngeloA: Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med339:80–851998
ChongBHPitneyWRCastaldiPA: Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet2:1246–12491982
CreekmoreFMOderdaGMPendletonRCBrixnerDI: Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy26:1438–14452006
GerlachRScheuerTBeckJWoszczykASeifertVRaabeA: Risk of postoperative hemorrhage after intracranial surgery after early nadroparin administration: results of a prospective study. Neurosurgery53:1028–10352003
GirolamiBPrandoniPStefaniPMTanduoCSabbionPEichlerP: The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood101:2955–29592003
GreinacherAEichlerPLietzTWarkentinTE: Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood106:2921–29222005
GreinacherAFarnerBKrollHKohlmannTWarkentinTEEichlerP: Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients Thromb Haemost94:132–1352005
GreinacherAPotzschBAmiralJDummelVEichnerAMueller-EckhardtC: Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost71:247–2511994
LeyvrazPFBachmannFHoekJBullerHRPostelMSamamaM: Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ303:543–5481991
LockeCFDooleyJGerberJ: Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar Thromb J3:42005
LubenowNEichlerPLietzTGreinacherA: Lepirudin in patients with heparin-induced thrombocytopenia—results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost3:2428– 24362005
MahlfeldKFrankeJSchaeperOKayserRGrasshoffH: [Heparin-induced thrombocytopenia as a complication of postoperative prevention of thromboembolism with unfractionated heparin/low molecular weight heparin after hip and knee prosthesis implantation.]. Unfallchirurg105:327–3312002. (Ger)
PouplardCMayMAIochmannSAmiralJVissacAMMarchandM: Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation99:2530–25361999
SzucsTDSchrammW: The cost-effectiveness of low-molecular-weight heparin vs unfractionated heparin in general and orthopaedic surgery: an analysis for the German healthcare system. Pharmacol Res40:83–891999
WallisDELewisBEWalengaJM: Failure of current strategies in the prevention of thrombosis in patients with heparininduced thrombocytopenia: a clinician's perspective. Semin Thromb Hemost25:1 Suppl3–71999